Experimental drug brincidofovir targets Hard-to-Treat lymphomas
NCT ID NCT06761677
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called brincidofovir in people with lymphoma (a type of blood cancer) that has returned or not improved after standard treatments. The trial has two parts: first, finding a safe dose in up to 18 people with various lymphomas, then testing that dose in 25 people with a rare subtype called ENKL. The goal is to see if the drug can shrink tumors and to understand its side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 43 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
May 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who are histopathologically diagnosed with ENKL based on the World Health Organization (WHO) Classification of Malignant Lymphoma 5th Edition (WHO-HAEM5) (can be enrolled in the Phase 1b part and the Phase 2 part) or patients diagnosed with EBV-positive nodal T- and NK-cell lymphoma (EBV + nTNKCL), nodal T-follicular helper cell lymphoma (nTFHcL) (including angioimmunoblastic T-cell lymphoma (AITL) as defined in the WHO Classification, 4th Edition), peripheral T-cell lymphoma not otherwise specified (PTCL, NOS), anaplastic large cell lymphoma (ALCL), diffuse large B-cell lymphoma (DLBCL) (e.g., DLBCL, NOS), or adult T-Cell Leukemia Lymphoma (ATLL) (can only be enrolled in the Phase 1b part) * Patients with relapsed or refractory lymphoma and previously treated with systemic chemotherapy (history of multidrug chemotherapy including L-asparaginase such as SMILE therapy for ENKL is mandatory) who are ineligible for other systemic therapies * Patients with the following Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): * Phase 1b part: 0-1 * Phase 2 part: 0-2 Exclusion Criteria: * Patients with another active malignant tumor requiring treatment * Patients with NCI-CTCAE Grade 2 or higher diarrhea (increase of 4 or more bowel movements per day compared to usual number of bowel movements) within 7 days prior to starting the first dose of BCV * Graft-Versus-Host Disease (GVHD) patients requiring immunosuppressive agents * Patients with a history of Cidofovir intolerance * Patients with a history of being diagnosed with cirrhosis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Relapsed or refractory adult T-cell leukemia lymphoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
8 sites in 3 countries. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cancer Institute Hospital Of JFCR
Kōtoku, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
Mie University Hospital
Tsu, Japan
-
National Cancer Center Hospital
Chūōku, Japan
-
National Cancer Centre Singapore
Singapore, Singapore
-
Okayama University Hospital
Okayama, Japan
-
Queen Mary Hospital
Hong Kong, China
-
Tokyo Metropolitan Komagome Hospital
Bunkyō City, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink Hard-to-Treat lymphoma tumors?
- New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
- New combo offers hope for aggressive lymphoma in diverse patients
- Experimental cocktail aims to tackle tough lymphoma
- Experimental lymphoma drug ASTX660 tested in tiny, terminated trial
- Double punch: CAR-T cells followed by antibodies may boost lymphoma remission